NXGL News & Events

NexGel announced data from the randomized, 30-patient, single-center institutional review board clinical study, funded by Innovative Optics, a supplier of safety products and personal protective equipment for medical, surgical and aesthetic healthcare facilities globally. Positive data from the study detailed a 95.6% reduction in plume concentration compared to the control side. Additionally, at 90 days posttreatment, the interventional site demonstrated a 37.2% mean reduction in hair density versus 26.7% on the control side. Mean pain scores were also significantly lower on the intervention side, with no adverse events were reported.

NexGel (NXGL) announced the appointment of Ian Blackman as CFO. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU). Most recently, Blackman served as CFO of McIntosh Group.

NexGel (NXGL) announced the closing of its previously announced license and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity (CELU), a regenerative and cellular medicine company. The Company has also launched BioNX Surgical, a new division of NEXGEL. The closing of this transaction will be financed under new terms and led by a $5.5 million strategic investment from Sequence LifeScience, a leader in regenerative medicine manufacturing. The transaction was financed through a convertible note with $0.60 conversion price and 50% warrant coverage with a strike price of $0.80.